For BeiGene, Bristol-Celgene deal is poised to have big ripple effects

For BeiGene, Bristol-Celgene deal is poised to have big ripple effects

STAT Plus: For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects

By REBECCA ROBBINS

IMAGINECHINA VIA AP

Like other leaders of China’s biotech sector, BeiGene is positioning itself as a global company, with ambitions to export drugs to the rest of the world.

READ MORE